Core Insights - Bright Minds Biosciences Inc. is collaborating with Firefly Neuroscience, Inc. to analyze EEG data from the BREAKTHROUGH study, which evaluates the safety and efficacy of BMB-101 for neurological disorders [1][2][3] - BMB-101 is a selective 5-HT2C receptor agonist aimed at treating refractory epilepsy disorders, including Absence Epilepsy and Developmental Epileptic Encephalopathy [1][2][3] - The BREAKTHROUGH study targets enrollment of 20 adult participants aged 18 to 65 years [2] Company Overview - Bright Minds Biosciences focuses on developing innovative treatments for neurological and psychiatric disorders, with a pipeline that includes compounds for epilepsy, depression, and other CNS disorders [5] - The company utilizes a unique platform of highly selective serotonergic agonists to address conditions with high unmet medical needs [5] Collaboration Details - The collaboration with Firefly follows a successful previous partnership that utilized Firefly's FDA-cleared BNA™ technology platform for data analysis in a Phase 1 study of BMB-101 [2][3] - Firefly's BNA™ technology leverages AI and machine learning to enhance diagnostic and treatment monitoring for brain health outcomes [6][7] Product Information - BMB-101 is designed to provide sustained seizure relief in hard-to-treat patient populations, avoiding receptor desensitization and tolerance development [3][4] - In Phase 1 studies, BMB-101 was safe and well-tolerated among 64 healthy volunteers, with no serious adverse events reported [4] Technology and Innovation - Firefly's BNA™ technology is based on a comprehensive database of EEGs from over 17,000 patients, enabling improved diagnosis and treatment evaluation for various neurological and mental disorders [6][7]
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data